Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
International Centre For Diarrhoeal Disease Research Bangladesh has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This distribution means that each of the 2 pending office actions is being reviewed under different technical standards and administrative leadership. Such a spread suggests that the center's research is diverse enough to be classified into separate specialized units at the USPTO.
GRASER, JENNIFER E is the busiest examiner, holding 1 busiest examiner pending action. With 2 pending office actions and 2 distinct examiners, the workload is balanced. This prevents the portfolio's progress from being tied to the discretion of just one person. However, the involvement of 2 distinct art units requires the prosecution team to adapt to two different sets of examination guidelines. Successfully resolving these 2 pending office actions will depend on meeting the unique requirements of the 2 distinct examiners involved while navigating their respective art units effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| TRAN, LIEN THUY | 1 | 28.6% | +26.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618314 | MICROBIOTA-DIRECTED FOODS TO REPAIR A SUBJECT'S GUT MICROBIOTA | TRAN, LIEN THUY | 24d overdue |
| 18728807 | BIFIDOBACTERIUM INFANTIS FORMULATIONS | GRASER, JENNIFER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618314 | MICROBIOTA-DIRECTED FOODS TO REPAIR A SUBJECT'S GUT MICROBIOTA | TRAN, LIEN THUY | 24d overdue |
| 18728807 | BIFIDOBACTERIUM INFANTIS FORMULATIONS | GRASER, JENNIFER E | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18728807 | BIFIDOBACTERIUM INFANTIS FORMULATIONS | GRASER, JENNIFER E | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 12, 2024 |
| 17618314 | MICROBIOTA-DIRECTED FOODS TO REPAIR A SUBJECT'S GUT MICROBIOTA | TRAN, LIEN THUY | 1793 | §103 | Final Rejection | 24d overdue | Pending | Dec 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial